Cite
HARVARD Citation
Kosmas, I. et al. (n.d.). Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study. Gynecological endocrinology. pp. 702-707. [Online].